WuXi AppTec (603259) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
26 Oct, 2026Executive summary
9M revenue reached RMB45.54bn, up 38.6% YoY; Continuing Operations revenue grew 46.3%, and backlog rose 36.4% to RMB76.74bn at Sept. 30.
Adjusted non-IFRS net profit increased 74.4% to RMB18.38bn.
FY2026 revenue and Continuing Operations growth guidance were raised, alongside higher adjusted free cash flow guidance.
Financial highlights
Q3 revenue was RMB16.64bn, up 38.0% YoY; attributable net income rose 136.7% to RMB8.32bn, including substantial disposal gains.
9M CAS net profit was RMB19.40bn, up 60.6%; net profit after non-recurring items was RMB16.48bn, up 73.0%.
9M adjusted non-IFRS net profit reached RMB18.38bn, up 74.4%; adjusted EPS was RMB6.31 versus RMB3.71.
9M operating cash flow increased 50.7% to RMB17.19bn; adjusted operating cash flow was RMB17.28bn, up 58.9%.
9M total profit was RMB24.05bn, up 59.9% YoY.
Outlook and guidance
FY2026 revenue guidance rose to RMB61.0–61.9bn from RMB58.5–60.5bn; Continuing Operations growth guidance increased to 40–42% from 35–39%.
FY2026 TIDES revenue is expected to grow ~47% YoY; adjusted non-IFRS net profit margin is expected to remain stable and resilient.
FY2026 capex guidance is RMB8.0–8.5bn; adjusted free cash flow guidance rose to RMB14.5–15.5bn from RMB13.5–14.5bn.
Latest events from WuXi AppTec
- H1 2026 saw record revenue, profit, and margin growth, with upgraded full-year outlook.603259
Q2 2026 - Q1 2026 revenue and profit surged, led by chemistry and CRDMO segment growth.603259
Q1 2026 - Record revenue and profit in 2025; 2026 guidance targets 18–22% growth and strong cash flow.603259
H2 2025 - Record 2025 results, robust pipeline, and major capacity expansions drive sustained growth.603259
44th Annual J.P. Morgan Healthcare Conference - Net profit more than doubled on strong CRDMO growth, margin gains, and asset sale gains.603259
H1 2025 - Q3 revenue rose sequentially, with TIDES growth and robust backlog despite profit decline.603259
Q3 2024 - H1 2024 revenue fell, but Q2 rebounded and TIDES grew 57.2%, with strong full-year guidance.603259
H1 2024 - Record Q4 and strong 2024 set stage for double-digit growth in 2025.603259
H2 2024 - Integrated CRDMO model, innovation, and ESG drive strong growth and resilience in 2024.603259
43rd Annual J.P. Morgan Healthcare Conference 2025